Global pharma major Lupin Limited (Lupin) has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for calcium, magnesium, potassium, and sodium oxybates oral solution, 0.5 g/mL, to market a generic equivalent of Xywav oral solution, 0.5 g/mL of Jazz Pharmaceuticals Ireland Limited. This product will be manufactured at Lupin’s Somerset facility in the US.
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch.
The net product sales for calcium, magnesium, potassium, and sodium oxybates oral solution (Xywav) were USD 958.4 million for the year ending December 2022 and USD 604.3 million for the first six months of 2023.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
